Ramucirumab (Synonyms: LY3009806) |
| カタログ番号GC19534 |
ラムシルマブは、固形腫瘍の治療のためのヒト VEGFR-2 アンタゴニストです。ラムシルマブは、VEGFR-2 の細胞外結合ドメインに結合し、VEGFR リガンド (VEGF-A、VEGF-C、および VEGF-D) の結合を妨げる組み換えヒト免疫グロブリン G1 モノクローナル抗体です。ラムシルマブは血管新生阻害剤でもあります。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 947687-13-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ramucirumab is a fully human monoclonal antibody (IgG1). Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis.
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *